Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging borders in HIV care education: Lessons from an online multidisciplinary international exchange programme.

HIV medicine·2025
Same author

Clinical Management of Hospitalized Patients With High-Consequence Infectious Diseases in England.

Health security·2024
Same author

Long versus short course anti-microbial therapy of uncomplicated Staphylococcus aureus bacteraemia: a systematic review.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2024
Same author

Exploring young people's attitudes to HIV prevention medication (PrEP) in England: a qualitative study.

BMJ open·2024
Same author

Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.

NEJM evidence·2024
Same author

Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis.

BMC infectious diseases·2023

Related Experiment Video

Updated: Jun 23, 2026

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
13:50

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients

Published on: June 11, 2011

Tuberculosis in people with HIV.

Brendan Payne1, Richard Bellamy

  • 1Department of Infection and Travel Medicine, James Cook University Hospital, Middlesbrough, UK.

BMJ Clinical Evidence
|May 21, 2009
PubMed
Summary

People with HIV and tuberculosis face a high risk of active disease and mortality. This review evaluates various treatments, including antiretrovirals and antimycobacterial combinations, for effectiveness and safety.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Clinical Medicine

Background:

  • Individuals co-infected with HIV and Mycobacterium tuberculosis have a significantly elevated risk (5-10% annually) of developing active tuberculosis.
  • Untreated tuberculosis in HIV-positive individuals is associated with high mortality rates.
  • A notable percentage (over 5%) of patients experience relapse even after successful tuberculosis treatment.

Purpose of the Study:

  • To systematically review and synthesize evidence on the effectiveness and safety of first-line and second-line treatments for tuberculosis in people living with HIV.
  • To address critical clinical questions regarding optimal therapeutic interventions for this vulnerable population.

Main Methods:

  • Conducted a systematic review of literature up to January 2007, searching major databases (Medline, Embase, Cochrane Library).

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Related Experiment Videos

Last Updated: Jun 23, 2026

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
13:50

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients

Published on: June 11, 2011

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

  • Included data from systematic reviews, randomized controlled trials (RCTs), and observational studies.
  • Incorporated safety information from regulatory agencies like the US FDA and UK MHRA.

    • Main Results:

    • Identified 19 studies (systematic reviews, RCTs, observational studies) meeting inclusion criteria.
    • Performed a GRADE evaluation to assess the quality of evidence for various interventions.
    • Synthesized findings on the effectiveness and safety of multiple treatment strategies.

    Conclusions:

    • Presents comprehensive information on adjuvant immunotherapy, antimycobacterial combinations, and conventional antituberculous treatments.
    • Evaluates directly-observed therapy, highly active antiretroviral treatment (HAART) initiation timing, and short-course rifampicin regimens.
    • Discusses secondary prophylaxis and unsupervised treatment options for tuberculosis in HIV-infected individuals.